Portal de investigação
Burden of Inflammatory Bowel Disease in Portugal
Dados básicos
- Código:
- Estudo Clínico Académico (Inflammatory Bowel)
- Protocolo:
- Estudo Clínico Académico (Inflammatory Bowel)
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2023
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelines
Farrugia, Y.; (...); Ellul, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae040. 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
D'Amico, Ferdinando; (...); Allocca, Mariangela
Article. 10.1111/eci.14283. 2024
Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis
Ferreira Duarte, M; (...); Morato, M
Article. 10.1111/jgh.16541. 2024
Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review
Gomes, SF; (...); Magro, F
Review. 10.3390/ijms252312852. 2024
Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''
Sousa, Paula, Magro, Fernando
Editorial Material. 10.1016/j.dld.2023.12.006. 2024
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study
Gisbert, Javier P.; (...); Vermeire, Severine
Article. 10.1093/ibd/izae162. 2024
Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study
Gisbert, J. P.; (...); Vermeire, S.
Meeting Abstract. 2024
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Peyrin-Biroulet, Laurent; (...); Danese, Silvio
Article. 10.1111/apt.17751. 2024
Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine
Borges-Carneiro, Filipa; (...); Magro, FERNANDO
Editorial Material. 10.20344/amp.21371. 2024
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
Allocca, Mariangela; (...); Fiorino, Gionata
Article. 10.1002/ueg2.12492. 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Parigi, TL; (...); Peyrin-Biroulet, L
Review. 10.1002/ueg2.12671. 2024
Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
Rosini, F.; (...); Svrcek, M.
Meeting Abstract. 2024
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis
Rubin, David T.; (...); Peyrin-Biroulet, Laurent
Article. 10.1093/ibd/izae204. 2024
Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
Magro, FERNANDO; (...); Feagan, Brian G.
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Magro, F.; (...); Daperno, M.
Meeting Abstract. 2024
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
Magro, Fernando; (...); Reinisch, Walter
Article. 10.1016/j.cgh.2023.11.010. 2024
Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials
Estevinho, M. M.; (...); Magro, F.
Meeting Abstract. 2024
Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension
D'Haens, G.; (...); Blumenstein, I.
Meeting Abstract. 2024
Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn's Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Loftus, E; (...); Lichtenstein, G
Meeting Abstract. 10.14309/01.ajg.0000995764.89379.2a. 2023
Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
De Sousa, H. Tavares; (...); Magro, F.
Meeting Abstract. 2024
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Pai, Rish K.; (...); Magro, FERNANDO
Review. 10.1080/17474124.2024.2326838. 2024
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Solitano, Virginia; (...); Danese, Silvio
Review. 10.1016/j.autrev.2023.103504. 2024
Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis
Poenariu, Ioan Sabin; (...); Estevinho, Maria Manuela
Article. 10.3390/biomedicines11123137. 2023
Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results
D'Amico, F.; (...); Dignass, A.
Meeting Abstract. 2024
Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?
Magro, Fernando, Estevinho, Maria Manuela, Valois, Andre
Article. 10.1093/jcag/gwad034. 2023
Microbiota therapeutics for inflammatory bowel disease: the way forward
Bethlehem, Lukas; (...); Colombel, Jean-Frederic
Article. 10.1016/S2468-1253(23)00441-7. 2024
Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib
Magro, F.; (...); Reinisch, W.
Meeting Abstract. 2024
Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
Temido, Maria Jose; (...); Peyrin-Biroulet, Laurent
Editorial Material. 10.1093/ecco-jcc/jjae136. 2024
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
Estevinho, Maria Manuela; (...); Magro, Fernando
Review. 10.1111/apt.18315. 2024
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Imbrizi, M, Magro, F, Coy, CSR
Review. 10.3390/ph16091272. 2023
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
D'Amico, F; (...); Danese, S
Article. 10.3390/jcm12196350. 2023
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
D'Amico, Ferdinando; (...); Danese, Silvio
Review. 10.1080/17474124.2024.2397650. 2024
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Fantini, Massimo Claudio; (...); Ghosh, Subrata
Article. 10.1093/ecco-jcc/jjae026. 2024
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD international consensus
Fantini, M. C.; (...); Ghosh, S.
Meeting Abstract. 2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Olivera, Pablo A.; (...); Peyrin-Biroulet, Laurent
Article. 10.1016/j.dld.2024.03.010. 2024
Proactive Infliximab monitoring improves the rates of transmural remission in Crohn's disease - a propensity score matched analysis
Fernandes, S. R.; (...); Magro, F.
Meeting Abstract. 2024
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis
Fernandes, SR; (...); Magro, F
Article. 10.1093/ibd/izad272. 2023
Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study
Dignass, A.; (...); Leitner, C.
Meeting Abstract. 2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study
D'Amico, Ferdinando; (...); Dignass, Axel
Article. 10.1002/ueg2.12572. 2024
Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial
Vermeire, S.; (...); Bolca, S.
Meeting Abstract. 2024
The degree of bowel remission predicts phenotype progression in Crohn's disease
Fernandes, Samuel Raimundo; (...); Magro, FERNANDO
Article. 10.1002/ueg2.12581. 2024
The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients
Magro, F.; (...); Santiago, M.
Meeting Abstract. 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Magro, Fernando; (...); Santiago, Mafalda
Article. 10.1093/ecco-jcc/jjae014. 2024
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
Sousa, P; (...); Magro, F
Article. 10.1016/j.dld.2023.10.027. 2024
Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease
Fernandes, SR; (...); Magro, F
Article. 10.1002/ueg2.12497. 2023
Transmural Remission Associates with a Lower Risk of Phenotype Progression in Crohn's Disease
Fernandes, S. R.; (...); Magro, F.
Meeting Abstract. 2024
Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results
Dignass, A.; (...); Magro, F.
Meeting Abstract. 2024
